Technology Development Fund announces 2014 grant awardees and results
Boston Children's Hospital's Technology Development Fund (TDF), administered by the Technology Innovation and Development Office (TIDO), is pleased to announce the recipients of the 2014 Technology Development Fund awards.
The TDF was created in 2009 to advance Boston Children's clinicians’ and researchers' promising technologies and support their translation into new devices, diagnostic tests and therapeutics that can benefit our patients and the broader public. In addition to providing financial support for selected projects, the TDF provides access to an external advisory board of industry experts in product development, who also serve as mentors for the selected projects. TDF also offers access to a network of preferred contract research organizations (CROs) with the expertise necessary to execute specific project plans. Approximately, 70% of funds for awarded projects are spent outside of the hospital setting through our network CROs to generate the independent validation required by investors and life science partners to consider licenses and partnerships.
The 2014 grant awardees—selected from 51 letters of intent submitted for consideration—include:
- Pro-siRNAs for cost-effective RNAi
Judy Lieberman, MD, PhD, PCMM/Medicine
- Small molecules for ex vivo maintenance and expansion of hematopoietic stem cells
Derrick Rossi, PhD PCMM/Medicine
- A high-throughput mouse model for optimizing therapeutic antibody specificity and affinity
Frederick Alt, PhD, PCMM/Medicine
- Therapeutic to reduce inflammation following severe burn injury
Michael Carroll, PhD, PCMM/Medicine
- Use of MAPS for the development of a tuberculosis vaccine
Richard Malley, MD, Infectious Disease/Medicine
- Development of a microphysiologic tissue construct to accelerate age-specific human vaccine development
Ofer Levy, MD, PhD, and Guzman Sanchez-Schmitz, Infectious Disease/Medicine
- Optimization of Pseudomonas aeruginosa vaccines
Gregory Priebe, MD, Anesthesiology
- Highly selective blood filtration with a novel circuit device to treat sepsis
Brian McAlvin, MD, and Daniel Kohane, MD, PhD, Anesthesiology
- Development of a novel magnetic needle for difficult surgeries
Kaifeng Liu, MD and Gary Visner, DO, Pulmonary/Medicine
- Rapid visualization of epileptogenic networks in epilepsy surgery planning
Joseph Madsen, MD, and Eun-Hyoung Park, Neurosurgery
- Children’s Research Integration System (ChRIS) – a web-based medical image data and workflow platform
Rudolph Pienaar, MD, Radiology
5 year results
For the first five cycles (2009-2013), Boston Children’s committed $5.1 million to support the development of 47 hospital innovations spanning multiple healthcare sectors including pharmaceuticals, diagnostics, medical devices, vaccines, regenerative medicine and healthcare IT. The $2.6 million in funding allocated to date has led to $13.2 million in follow-on funding for projects from external sources, including the National Institutes of Health, the Department of Defense, the American Heart Association and the Gates Foundation. “The strong support of the TDF by Boston Children’s over its first five years has enabled real advancement of Hospital technology. We are grateful for the continuing support, proud of the TDF’s excellent track record of funded projects, and delighted by the high caliber proposals this year,” said Jane Amara, PhD, TIDO's interim director.
Since 2009, TDF awards have led to:
- The establishment of four startup companies including Epidemico, Inc., which was recently acquired by Booz Allen Hamilton, and Affinivax, launched with a $4 million investment from the Bill & Melinda Gates Foundation. The four new companies (medical device, vaccine and software) have collectively received $13.6M in seed funding from various venture capitalists, the FDA, and foundations.
- 10 novel partnerships with external academic programs and biomedical companies that expanded product development expertise, funding, resources and tools to accelerate the development of Boston Children’s innovations.
- Nine new patent applications and over 20 publications and manuscripts.